A multicenter, randomized open-label, pilot study to explore the benefit of a conversion from a twice a day administration of cyclosporine microemulsion to a once a day administration and to identify the C2 ranges to target after conversion in stable liver transplant recipients

Trial Profile

A multicenter, randomized open-label, pilot study to explore the benefit of a conversion from a twice a day administration of cyclosporine microemulsion to a once a day administration and to identify the C2 ranges to target after conversion in stable liver transplant recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2011

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Liver transplant rejection
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 11 Feb 2011 Actual patient number is 61 according to ClinicalTrials.gov.
    • 31 Jan 2011 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top